Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 19,060 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 19,060 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $14.18, for a total value of $270,270.80. Following the transaction, the chief operating officer owned 408,160 shares in the company, valued at $5,787,708.80. The trade was a 4.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.15, for a total transaction of $250,639.00.
• On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.77, for a total transaction of $243,396.20.
• On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.56, for a total transaction of $258,453.60.
• On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.83, for a total value of $458,855.03.
• On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.45, for a total transaction of $275,417.00.
• On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total transaction of $263,599.80.
• On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.37, for a total value of $254,832.20.
• On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.18, for a total transaction of $251,210.80.
• On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.41, for a total transaction of $255,594.60.
• On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07.

Adaptive Biotechnologies Stock Down 3.1%

NASDAQ ADPT opened at $14.08 on Friday. Adaptive Biotechnologies Corporation has a 12-month low of $6.77 and a 12-month high of $20.76. The company has a 50-day simple moving average of $14.69 and a two-hundred day simple moving average of $15.98. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of -35.20 and a beta of 2.29.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. During the same quarter in the previous year, the company posted ($0.23) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% on a year-over-year basis. Equities analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ameriprise Financial Inc. lifted its holdings in shares of Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after acquiring an additional 3,299,635 shares during the period. Westfield Capital Management Co. LP acquired a new stake in Adaptive Biotechnologies during the 4th quarter worth about $65,942,000. Geode Capital Management LLC grew its position in Adaptive Biotechnologies by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after purchasing an additional 110,825 shares during the period. Finally, State Street Corp grew its position in Adaptive Biotechnologies by 3.3% during the 4th quarter. State Street Corp now owns 3,181,644 shares of the company’s stock worth $51,670,000 after purchasing an additional 102,362 shares during the period. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ADPT has been the subject of several analyst reports. JPMorgan Chase & Co. raised their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Guggenheim raised their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. BTIG Research lifted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.